Abstract C068: Construction of preclinical study model for optimal anticancer drug selection using PDX model in pancreatic cancer
Ryota Tanaka(Osaka City University), Takeaki Ishizawa(The University of Tokyo), Ken Kageyama(Tokyo Metropolitan University), Go Ohira(Osaka Metropolitan University), Shimpei Eguchi(Tokyo Metropolitan University), Hiroji Shinkawa(Osaka Metropolitan University), Shigeaki Kurihara(Osaka Metropolitan University), Kenjiro Kimura(Osaka Metropolitan University), Masahiko Kinoshita(Metropolitan University), Shuhei Kushiyama(Osaka Metropolitan University), Akira Yamamoto(Osaka Metropolitan University), Kohei Nishio(Osaka Metropolitan University), Naoki Tani(Osaka Gakuin University)
Cited by 1
Related Papers
PINK1 autophosphorylation upon membrane potential dissipation is essential for Parkin recruitment to damaged mitochondria
|Nature Communications|2012|599
Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1/2 trial
|The Lancet|2014|436
MEIOSIN Directs the Switch from Mitosis to Meiosis in Mammalian Germ Cells
|Developmental Cell|2020|211
Successful Translation of Fluorescence Navigation During Oncologic Surgery: A Consensus Report
|Journal of Nuclear Medicine|2015|147